N/A
Completed N=21
Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler
Gene Expression
Source: ClinicalTrials.gov NCT05620043 ↗
Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcomePrimary: Gene Expression — 1; 1; 1; 4 Significantly upregulated genes
Summary
To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Gene Expression |
1; 1; 1; 4; 2; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Subject with a minimum of shallow nasolabial fold (NLF) contour deficiencies as assessed via the wrinkle assessment scale
- Subject with identical WAS scores on both NLFs
- Ability of giving consent for participation in the study
- Agreement to have skin biopsies on NLFs
Exclusion Criteria
- Significant NLF asymmetry, or different WAS score on each NLF
- Pregnant, planning pregnancy during the course of the study or breastfeeding
- History of allergy or hypersensitivity to any ingredient of the treatment products
- History of allergy or hypersensitivity to anesthetics or lidocaine
Data sourced from ClinicalTrials.gov (NCT05620043). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.